1 day Ago By ABMN Staff
Bank of New York Mellon Corp raised its position in shares of Altimmune, Inc. ( NASDAQ:ALT – Free Report ) by 28.6% in the 2nd quarter, HoldingsChannel.
com reports. The institutional investor owned 243,808 shares of the company’s stock after purchasing an additional 54,154 shares during the quarter. Bank of New York Mellon Corp’s holdings in Altimmune were worth $1,621,000 at the end of the most recent reporting period.
Several other institutional investors have also added to or reduced their stakes in ALT. Horizon Wealth Management LLC purchased a new position in Altimmune during the 2nd quarter valued at $66,000. Hennion & Walsh Asset Management Inc.
bought a new stake in Altimmune during the 2nd quarter valued at $860,000. SG Americas Securities LLC raised its position in Altimmune by 542.8% during the 2nd quarter.
SG Americas Securities LLC now owns 254,571 shares of the company’s stock valued at $1,693,000 after purchasing an additional 214,968 shares in the last quarter. Cetera Advisors LLC raised its position in Altimmune by 19.6% during the 1st quarter.
Cetera Advisors LLC now owns 60,800 shares of the company’s stock valued at $619,000 after purchasing an additional 9,977 shares in the last quarter. Finally, Farallon Capital Management LLC raised its position in shares of Altimmune by 1,282.4% in the 1st quarter.
Farallon Capital Management LLC now owns 470,000 shares of the company’s stock worth $4,785,000 after acquiring an additional 436,000 shares in the last quarter. Hedge funds and other institutional investors own 78.05% of the company’s stock.
Wall Street Analyst Weigh In Several research analysts have recently commented on the company. B. Riley reissued a “buy” rating and issued a $20.
00 price target on shares of Altimmune in a research report on Monday, August 12th. Evercore ISI upgraded Altimmune to a “strong-buy” rating in a research note on Friday, August 9th. Piper Sandler restated an “overweight” rating and set a $25.
00 target price on shares of Altimmune in a research note on Friday, June 21st. Finally, HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Altimmune in a research note on Thursday, August 22nd.
Two analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $18.80.
Insider Buying and Selling In related news, Director David Drutz sold 16,011 shares of the stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $6.90, for a total value of $110,475.
90. Following the completion of the sale, the director now owns 41,958 shares of the company’s stock, valued at $289,510.20.
The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website . 4.10% of the stock is currently owned by insiders.
Altimmune Stock Performance Altimmune stock opened at $7.43 on Thursday. Altimmune, Inc.
has a fifty-two week low of $2.09 and a fifty-two week high of $14.84.
The company has a market cap of $526.80 million, a PE ratio of -4.67 and a beta of 0.
08. The business’s 50-day simple moving average is $6.72 and its two-hundred day simple moving average is $7.
46. Altimmune ( NASDAQ:ALT – Get Free Report ) last issued its earnings results on Thursday, August 8th. The company reported ($0.
35) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01).
The company had revenue of $0.01 million during the quarter. Altimmune had a negative return on equity of 53.
09% and a negative net margin of 24,778.97%. During the same quarter last year, the firm earned ($0.
32) EPS. As a group, analysts predict that Altimmune, Inc. will post -0.
54 EPS for the current fiscal year. Altimmune Profile ( Free Report ) Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.
Recommended Stories Want to see what other hedge funds are holding ALT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Altimmune, Inc. ( NASDAQ:ALT – Free Report ).
Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with MarketBeat.com's FREE daily email newsletter ..
